Special Issue

Advances in Cancer Glycobiology

Message from the Guest Editors

In this special issue, contributions to this Special Issue will span, but are not limited to: 1) advances in the identification of the underlying role of glycoconjugates and their alterations in various tumors; 2) the molecular mechanisms that involve glycan/glycoconjugate modifications and their role in various aspects of tumor development, progression, EMT, invasion, metastasis and cancer relapse; 3) the use of glycoconjugate alterations found in neoplastic tissues as diagnostic and prognostic markers; and 4) novel cancer therapeutic strategies that target glycan/glycoconjugate modifications and support the 3P concept of modern medicine.

Guest Editors

Prof. Dr. Dietrich Büsselberg

Dr. Samson Mathews Samuel

Prof. Dr. Ajaikumar B. Kunnumakkara

Prof. Dr. Peter Kubatka

Deadline for manuscript submissions

closed (5 February 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/120046

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

